X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
index medicus (21) 21
melanoma (17) 17
article (15) 15
braf (15) 15
melanoma - drug therapy (13) 13
melanoma - pathology (13) 13
oncology (11) 11
proto-oncogene proteins b-raf - antagonists & inhibitors (11) 11
neoplasms (10) 10
melanoma - genetics (9) 9
proto-oncogene proteins b-raf - genetics (9) 9
cell line, tumor (8) 8
mutation (8) 8
protein kinase inhibitors - pharmacology (8) 8
melanoma - metabolism (7) 7
mutations (7) 7
acquired-resistance (6) 6
animals (6) 6
cancer (6) 6
cell biology (6) 6
mek inhibition (6) 6
metastatic melanoma (6) 6
proto-oncogene proteins b-raf - metabolism (6) 6
skin neoplasms - drug therapy (6) 6
skin neoplasms - pathology (6) 6
dermatology (5) 5
digestive system diseases (5) 5
membrane proteins - genetics (5) 5
molecular targeted therapy (5) 5
nras (5) 5
skin neoplasms - genetics (5) 5
b-raf (4) 4
biochemistry & molecular biology (4) 4
cutaneous melanoma (4) 4
female (4) 4
gene mutations (4) 4
gtp phosphohydrolases - genetics (4) 4
indoles - pharmacology (4) 4
malignant-melanoma (4) 4
mediates resistance (4) 4
open-label (4) 4
phosphatidylinositol 3-kinases - antagonists & inhibitors (4) 4
proteins (4) 4
proteomics (4) 4
resistance (4) 4
signal transduction (4) 4
sulfonamides - pharmacology (4) 4
vemurafenib (4) 4
antineoplastic agents - therapeutic use (3) 3
apoptosis (3) 3
biochemical research methods (3) 3
care and treatment (3) 3
cells (3) 3
drug resistance, neoplasm (3) 3
endocrine system diseases (3) 3
genetic aspects (3) 3
health aspects (3) 3
improved survival (3) 3
medicine, research & experimental (3) 3
metastasis (3) 3
mice (3) 3
mitogen-activated protein kinase kinases - metabolism (3) 3
mutant melanoma (3) 3
phase-ii trial (3) 3
phosphatidylinositol 3-kinases - metabolism (3) 3
phosphorylation (3) 3
raf inhibitors (3) 3
research (3) 3
signal transduction - drug effects (3) 3
survival (3) 3
up-regulation (3) 3
amuvatinib (2) 2
analysis (2) 2
antineoplastic agents - pharmacology (2) 2
azabicyclo compounds - pharmacology (2) 2
biochemistry (2) 2
braf mutations (2) 2
cell cycle (2) 2
cell-lines (2) 2
cellular biology (2) 2
cellular signal transduction (2) 2
chemotherapy (2) 2
disease management (2) 2
disease progression (2) 2
drug resistance (2) 2
drug resistance, neoplasm - genetics (2) 2
fibroblasts (2) 2
gene expression regulation, neoplastic (2) 2
genetics & heredity (2) 2
growth (2) 2
immunotherapy (2) 2
indoles - therapeutic use (2) 2
inhibitor resistance (2) 2
invasion (2) 2
kinase inhibitor (2) 2
kinases (2) 2
ligands (2) 2
male (2) 2
mapk (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 09/2016, Volume 139, Issue 6, pp. 1195 - 1201
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2015, Volume 21, Issue 4 Supplement, pp. IA04 - IA04
Journal Article
Genes and Cancer, ISSN 1947-6019, 2015, Volume 6, Issue 9-10, pp. 367 - 368
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 7, pp. 2750 - 2760
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of a tissue array covering all... 
METASTATIC MELANOMA | APOPTOSIS | PROTEIN | ONCOLOGY | PHOSPHORYLATION | CUTANEOUS MELANOMA | RAF KINASE | CANCER | MEDIATES RESISTANCE | LINES | ERK | RNA, Small Interfering - genetics | Up-Regulation | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Bcl-2-Like Protein 11 | Melanoma - genetics | Apoptosis Regulatory Proteins - genetics | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Apoptosis Regulatory Proteins - biosynthesis | Melanoma - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | PTEN Phosphohydrolase - deficiency | Membrane Proteins - genetics | PTEN Phosphohydrolase - biosynthesis | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Membrane Proteins - biosynthesis | Membrane Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Mutation | RNA, Small Interfering - administration & dosage | Index Medicus | PTEN | melanoma | BRAF | PLX4032 | therapy | resistance
Journal Article
Molecular & Cellular Oncology, ISSN 2372-3556, 10/2015, Volume 2, Issue 4, pp. e1008291 - e1008291
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using... 
melanoma | BRAF | metastasis | ephrin | resistance
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 8 Supplement, pp. 5370 - 5370
Journal Article
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 10/2010, Volume 19, Issue 10 Supplement, pp. A66 - A66
Journal Article
PROTEOMICS, ISSN 1615-9853, 01/2015, Volume 15, Issue 2-3, pp. 327 - 339
Basal and kinase inhibitor driven adaptive signaling has been examined in a panel of melanoma cell lines using phosphoproteomics in conjunction with pathway... 
Signaling | NRAS | BRAF | Biomedicine | Phosphoproteomics | Melanoma | CELLS | QUANTITATIVE PROTEOMICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | INHIBITOR RESISTANCE | BIOCHEMICAL RESEARCH METHODS | ACQUIRED-RESISTANCE | CANCER | METASTATIC MELANOMA | MEK INHIBITION | PKC-DELTA | MUTATIONS | MEDIATES RESISTANCE | Melanoma - metabolism | Membrane Proteins - genetics | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Mitogen-Activated Protein Kinase Kinases - metabolism | GTP Phosphohydrolases - metabolism | Signal Transduction - drug effects | GTP Phosphohydrolases - genetics | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Indoles - pharmacology | Membrane Proteins - metabolism | Protein Kinase Inhibitors - pharmacology | Mutation | Phosphorylation - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Proteins | Glucose metabolism | Synthesis | Gene mutations | Glycogen | Analysis | Cellular signal transduction | Biological response modifiers | Phosphotransferases | Phosphorylation | Regulators | Adaptive systems | Protein kinase C | Divergence | Peptides | Phosphotyrosine | Homology | Kinases | Phosphatase | Signal transduction | Epidermal growth factor | Cell cycle | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Genotypes | Tyrosine | Tensin | Cyclin-dependent kinases | Stat3 protein | Extracellular signal-regulated kinase | Glycogen synthase kinase 3 | MAP kinase | Phospholipase C | Phospholipase | Cell lines | Cytoskeleton | Transduction | Interferon | PTEN protein | Guanosinetriphosphatase | Protein-tyrosine-phosphatase | Index Medicus | phosphoproteomics | melanoma | signaling
Journal Article
PROTEOMICS, ISSN 1615-9853, 01/2015, Volume 15, Issue 2-3, pp. 327 - 339
Journal Article
Oncogene, ISSN 0950-9232, 03/2016, Volume 35, Issue 10, pp. 1225 - 1235
Journal Article
Molecular and Cellular Proteomics, ISSN 1535-9476, 2014, Volume 13, Issue 7, pp. 1844 - 1854
The evolution of cancer therapy into complex regimens with multiple drugs requires novel approaches for the development and evaluation of companion biomarkers.... 
PHASE-II TRIAL | HSP90 INHIBITOR | NRAS | BIOCHEMICAL RESEARCH METHODS | BRAF INHIBITOR RESISTANCE | TARGETED MEK INHIBITION | ABSOLUTE QUANTIFICATION | PROTEINS | CANCER | REPRODUCIBILITY | TANESPIMYCIN | Azabicyclo Compounds - pharmacology | Neoplasm Transplantation | Humans | Drug Resistance, Neoplasm | NF-kappa B - metabolism | Transplantation, Heterologous | Chromatography, High Pressure Liquid | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors | Piperidines - pharmacology | RNA Interference | Melanoma - genetics | Mass Spectrometry | Indoles - pharmacology | Phthalic Acids - pharmacology | Receptor, Platelet-Derived Growth Factor beta - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Membrane Proteins - genetics | Mice, SCID | Sulfonamides - pharmacology | beta Catenin - genetics | Animals | MAP Kinase Signaling System - drug effects | Wnt Signaling Pathway - genetics | GTP Phosphohydrolases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Proteomics | Cell Line, Tumor | Benzimidazoles - pharmacology | Biomarkers, Tumor - genetics | Mice | Mice, Inbred BALB C | RNA, Small Interfering | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus | Research
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 05/2014, Volume 27, Issue 3, pp. 465 - 478
This study investigates the mechanism of action behind the long‐term responses (12–16 months) of two BRAF WT melanoma patients to the AKT inhibitor MK ‐2206 in... 
melanoma | apoptosis | BRAF | AKT | autophagy | chemotherapy | Chemotherapy | Autophagy | Melanoma | Apoptosis | CANCER-CELLS | CONTROLLED-TRIAL | MUTANT MELANOMA | IMPROVED SURVIVAL | OPEN-LABEL | CELL-SURVIVAL | CELL BIOLOGY | DERMATOLOGY | METASTATIC MELANOMA | IN-VITRO | NRAS | ONCOLOGY | MUTATIONS | Clone Cells - drug effects | Reactive Oxygen Species - metabolism | Skin Neoplasms - drug therapy | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Melanoma - enzymology | Male | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Autophagy - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Skin Neoplasms - enzymology | Female | Neoplasm Proteins - genetics | Paclitaxel - administration & dosage | Spheroids, Cellular | Skin Neoplasms - pathology | Tumor Stem Cell Assay | Carboplatin - administration & dosage | Melanoma - pathology | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Heterocyclic Compounds, 3-Ring - administration & dosage | Melanoma - drug therapy | Aged | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Antioxidants | Analysis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4774, 7/2013, Volume 10, Issue 7, pp. 390 - 399
The clinical benefits of BRAF inhibition in patients with advanced-stage BRAF -mutant melanoma are now well established. Although the emergence of cutaneous... 
Journal Article
Melanoma research, ISSN 0960-8931, 10/2014, Volume 24, Issue 5, pp. 448 - 453
Effective targeted therapy strategies are still lacking for the 15–20% of melanoma patients whose melanomas are driven by oncogenic NRAS . We here report on... 
MP470 | RTK | melanoma | NRAS | BRAF | amuvatinib
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 5222 - 5222
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.